Sergio Rutella

Professor Sergio Rutella is a licensed haematologist and Director of the John van Geest Cancer Research Centre at Nottingham Trent University. With over 230 peer-reviewed publications and an H-index of 67, his work bridges translational immunology and cancer biology to advance antibody-based therapies and haematopoietic stem cell transplantation.

• PhD in Experimental Haematology (Catholic University Medical School, Rome)
• Specialisation in Haematology (summa cum laude, Rome)
• Full Registration with Italian Medical Council
• GMC Specialist Registration in Haematology (UK)

Rutella's research focuses on AML immunotherapy, dissecting how IFN-gamma signaling and TP53 mutations drive immune evasion. His team uses single-cell RNA sequencing, spatial transcriptomics, and bioinformatics to identify predictive biomarkers and tailor precision immunotherapy clinical trials.

His 2020–2025 publications reveal trends in immune landscape analysis, checkpoint modulators, and AML microenvironment. Notable findings include the role of IFN-stimulated genes in chemotherapy resistance and the 3-gene signature predicting AML outcomes.

• Fellow, Royal Society of Biology (2022)
• Vice Chancellor's Outstanding Researcher Award (2019)
• Scientific Advisory Board, DFG Collaborative Research Centre
• Editorial Roles: Journal of Clinical Medicine, Frontiers in Immunology

As Principal Investigator for >£12M in grants (Wugen, MacroGenics, Sheffield Charity, Kura Oncology), Rutella collaborates with institutions in Germany, Italy, USA, and Qatar. His lab's work on flotetuzumab and memory-like NK cells has been featured in Blood, Science Translational Medicine, and Blood Cancer Discovery.